Home Inherited Disease and Carrier Screening Hereditary Hearing Loss Genetic Test: GJB2, GJB6, Mitochondrial DNA, and Results

Hereditary Hearing Loss Genetic Test: GJB2, GJB6, Mitochondrial DNA, and Results

By
Vita Library
-
5
Understand GJB2, GJB6-region, and mitochondrial hearing-loss testing, including carrier findings, maternal inheritance, aminoglycoside risk, panel limits, and family results.

A hereditary hearing loss genetic test searches for inherited changes that affect the inner ear, auditory nerve, or related structures. Common targets include GJB2, nearby deletions at the GJB6 region, and mitochondrial DNA variants such as MT-RNR1 changes associated with aminoglycoside sensitivity. However, hearing loss is one of the most genetically diverse human traits, so a modern multigene panel often provides more useful information than testing only one or two genes. Results can clarify cause, inheritance, recurrence risk, medication precautions, and whether other organs need surveillance. They can also guide testing for relatives and sometimes influence cochlear implant expectations or reproductive planning. Interpretation must be matched to the hearing pattern, age at onset, progression, imaging, physical findings, and family history. One GJB2 variant is usually carrier status rather than a complete diagnosis, while mitochondrial findings follow maternal inheritance and may be present at different levels in different tissues.

  • GJB2 is a common cause of autosomal recessive nonsyndromic sensorineural hearing loss.
  • One pathogenic GJB2 variant usually does not explain recessive hearing loss by itself.
  • Large deletions near GJB6 can disrupt regulation of GJB2 and may pair with a GJB2 variant.
  • MT-RNR1 variants can increase susceptibility to aminoglycoside-induced hearing loss and follow maternal inheritance.
  • A negative GJB2 test does not rule out hereditary hearing loss because many other genes can be involved.
  • Genetic results should be interpreted alongside formal audiology and a syndromic evaluation.

Table of Contents

Building the clinical picture

Hearing loss can be conductive, sensorineural, or mixed. Conductive loss involves sound transmission through the outer or middle ear. Sensorineural loss involves the cochlea or auditory pathway. Genetic causes are especially common in congenital and childhood sensorineural hearing loss, but inherited hearing loss can begin in adolescence or adulthood and may progress slowly.

The genetic test is most useful when the phenotype is described precisely. Important details include:

  • age at identification or onset;
  • whether one or both ears are affected;
  • mild, moderate, severe, or profound degree;
  • stable versus progressive course;
  • frequency pattern on the audiogram;
  • vestibular symptoms, tinnitus, or auditory neuropathy;
  • temporal-bone imaging findings;
  • newborn hearing-screen results;
  • infections, prematurity, noise, trauma, and ototoxic medication exposure;
  • eye, kidney, thyroid, heart, neurologic, skin, pigment, or balance findings;
  • hearing loss, deafness, sudden death, renal disease, or vision loss in relatives.

“ Nonsyndromic” means hearing loss is the main recognized feature. “Syndromic” means it occurs with findings in other organs. The distinction may change over time. A young child can first appear to have isolated hearing loss before retinal, thyroid, renal, cardiac, or neurologic features become apparent. A gene diagnosis can therefore reveal surveillance needs before symptoms develop.

Newborn hearing screening detects hearing status; it does not identify the cause. A baby who does not pass screening needs prompt diagnostic audiology and medical follow-up, regardless of whether genetic testing has started. Conversely, some progressive or mild genetic forms can pass newborn screening.

The initial evaluation commonly includes audiology, otolaryngology, medical and developmental history, and a genetics assessment. Imaging, electrocardiography, ophthalmology, renal testing, thyroid evaluation, or congenital infection testing may be added when the pattern suggests them. A newborn screening follow-up guide helps distinguish screening from diagnostic evaluation.

A genetic panel should be chosen after this clinical review, not used as a replacement for it.

How GJB2 results are read

GJB2 encodes connexin 26, a protein that forms channels between cells in the cochlea. Pathogenic variants can cause autosomal recessive nonsyndromic hearing loss, often called DFNB1A. Some specific variants cause autosomal dominant hearing loss or syndromic skin-and-hearing disorders, so inheritance cannot be assumed from the gene name alone.

Two pathogenic variants in trans

Two pathogenic or likely pathogenic GJB2 variants on opposite gene copies usually establish GJB2-related autosomal recessive hearing loss when the phenotype fits. The variants may be identical or different. Parental testing can show that one came from each parent and confirm that they are in trans.

Severity varies by genotype. Variants that truncate connexin 26 are often associated with more severe congenital loss, while some nontruncating variants are associated with milder hearing loss. These are broad tendencies, not guarantees. People with the same variants can have different thresholds and progression.

GJB2-related recessive hearing loss is often bilateral and congenital, and it may be severe to profound, but mild or moderate presentations occur. It is commonly nonsyndromic, so a positive result can spare a child some unnecessary testing while still requiring routine clinical assessment.

One pathogenic variant

One pathogenic GJB2 variant usually means the person is a carrier. It does not by itself establish recessive GJB2-related hearing loss. The next steps depend on context:

  • verify that sequencing covered the entire relevant region;
  • assess deletion/duplication and known upstream deletions;
  • consider whether a second variant could be deep intronic, regulatory, mosaic, or technically difficult;
  • broaden testing to other hearing-loss genes;
  • review whether the detected variant has a dominant association.

A frequent error is to stop after finding one familiar founder variant and attribute all hearing loss to it. A carrier result may be incidental, especially on a large panel.

No GJB2 variant

A negative result does not rule out a genetic cause. It may simply mean the cause lies in another gene. Even comprehensive GJB2 testing has residual limitations, including deep regulatory variants and complex rearrangements.

Variant of uncertain significance

A GJB2 VUS should not be counted as a confirmed second disease allele. Audiologic fit, population frequency, functional evidence, segregation, and expert classification all matter. Testing relatives can help only when the laboratory or genetics team has a specific plan.

Reports may use older variant names or describe recurrent variants differently across transcripts. Confirm that family members are tested for the exact DNA change rather than a remembered protein label.

What GJB6-region deletions mean

GJB6 encodes connexin 30 and sits near GJB2 at the DFNB1 locus. Historical reports often described certain large deletions as “GJB6 deletions” causing digenic GJB2/GJB6 hearing loss. Current understanding is more precise: recurrent deletions in the region can remove regulatory elements needed for GJB2 expression, even when the GJB2 coding sequence on that chromosome is intact.

Two recurrent deletions are often written del(GJB6-D13S1830) and del(GJB6-D13S1854) or with laboratory-specific nomenclature. Their frequency varies greatly by ancestry and population. They are not a universal explanation for every person with one GJB2 variant.

A clinically important pattern can occur when:

  • one chromosome carries a pathogenic GJB2 coding variant; and
  • the other chromosome carries a large upstream deletion that disrupts GJB2 function.

Together, these can produce recessive DFNB1 hearing loss. Phase is essential. If the coding variant and deletion are on the same chromosome, the other GJB2 copy may still function normally and the interpretation changes.

Not every hearing-loss panel detects these deletions. Standard sequencing may identify small variants while missing large copy-number changes. The report should state whether recurrent GJB6-region deletions, GJB2 exon-level changes, and broader copy-number variants were assessed.

The gene label can also mislead in another way. Pathogenic variants within GJB6 itself can cause other phenotypes, including some dominant conditions, but those are distinct from the common upstream-deletion mechanism. The laboratory should specify whether the result is a sequence variant in GJB6, a deletion including GJB6, or a regulatory deletion affecting GJB2.

When a person has one GJB2 variant and negative deletion testing, a broad panel is usually more informative than repeatedly ordering additional limited GJB6 assays. Modern hearing-loss genetics includes many genes with copy-number variants, pseudogenes, repeat regions, and mitochondrial variants that require dedicated methods.

Mitochondrial hearing loss and MT-RNR1

Mitochondrial DNA is separate from nuclear DNA and is usually inherited from the egg. A person with a pathogenic mitochondrial variant can transmit it to all children if that person is the mitochondrial parent; a person who inherited the variant from the sperm side does not usually transmit it onward. This maternal pattern differs from autosomal recessive GJB2 inheritance.

MT-RNR1 encodes mitochondrial 12S ribosomal RNA. Certain variants, especially m.1555A>G and several others, increase susceptibility to sensorineural hearing loss after exposure to aminoglycoside antibiotics such as gentamicin, tobramycin, amikacin, or streptomycin. Hearing loss can be severe and permanent, sometimes after ordinary dosing. Some carriers develop hearing loss without a recognized aminoglycoside exposure, while others remain unaffected.

A confirmed clinically significant MT-RNR1 result should be entered prominently in the medical record and medication-safety systems. Aminoglycosides are generally avoided when effective alternatives exist. In a life-threatening infection, clinicians must balance genetic risk against the need for rapid antimicrobial treatment; a genetic report should never lead a patient to refuse emergency therapy without medical discussion.

Mitochondrial results can be homoplasmic, meaning nearly all measured mitochondrial DNA molecules carry the variant, or heteroplasmic, meaning a mixture is present. Heteroplasmy level may differ between blood, urine, hair follicles, muscle, and inner-ear tissues. A low or negative blood level does not always exclude a mitochondrial variant found in another tissue or relative.

Other mitochondrial genes and variants can cause isolated or syndromic hearing loss. For example, MT-TL1 variants may occur with maternally inherited diabetes and deafness, and broader mitochondrial disorders can involve neurologic, muscular, cardiac, endocrine, or visual findings. A limited MT-RNR1 test will not detect all mitochondrial causes.

The mitochondrial DNA test guide explains maternal inheritance, heteroplasmy, and tissue selection in more detail.

Family testing follows the maternal line. Siblings who share the same mitochondrial mother may be at risk, as may the mother’s siblings and their maternal relatives. Medication precautions may be clinically useful even in relatives with normal hearing.

Why a broader panel may be better

Hundreds of genes have been linked to hearing loss, and several common causes are not detected by a GJB2/GJB6-only test. A phenotype-guided multigene panel can include genes associated with nonsyndromic hearing loss, auditory neuropathy, enlarged vestibular aqueduct, Usher syndrome, Pendred syndrome, branchio-oto-renal syndrome, Alport syndrome, Waardenburg syndrome, and other conditions.

The technical design matters. A useful panel may need:

  • sequence analysis for substitutions and small insertions or deletions;
  • exon-level deletion and duplication detection;
  • reliable analysis of genes with pseudogenes, such as STRC;
  • detection of large deletions involving STRC and CATSPER2;
  • mitochondrial DNA analysis when indicated;
  • selected difficult variants or repeat expansions;
  • an option for exome, genome, or reanalysis when the panel is negative.

STRC deletions and variants are a common cause of mild-to-moderate autosomal recessive hearing loss. Because STRC has a highly similar pseudogene, ordinary short-read analysis can miss or misassign variants. A panel that lists STRC without a validated method may provide false reassurance.

SLC26A4 can be associated with enlarged vestibular aqueduct and Pendred syndrome. USH2A, MYO7A, and other Usher genes can cause hearing loss before retinal degeneration becomes obvious. OTOF can cause auditory neuropathy and may have implications for cochlear implant timing and emerging therapies. KCNQ1 and KCNE1 can link hearing loss with a dangerous heart-rhythm disorder in Jervell and Lange-Nielsen syndrome.

This breadth is why a negative limited test should not end the evaluation when hearing loss is strongly suspected to be genetic. A multigene panel result guide can help compare panel scope, coverage, and residual risk.

Panel selection should still avoid indiscriminate gene lists with weak disease evidence. ClinGen gene curation can help laboratories and clinicians distinguish definitive hearing-loss genes from disputed or limited relationships. A larger panel increases the chance of uncertain and incidental findings, so clinical relevance remains more important than raw gene count.

Positive, negative, and uncertain results

A hearing-loss report becomes actionable only after the genotype is matched to the expected inheritance and phenotype.

Positive or diagnostic

A diagnostic result generally identifies the required pathogenic variant pattern: two variants for an autosomal recessive condition, one variant for an autosomal dominant condition, a pathogenic X-linked variant interpreted according to sex chromosomes, or a clinically significant mitochondrial variant. The result may establish etiology, but it does not perfectly predict severity or treatment response.

The clinician should check whether the gene is syndromic. A result may trigger eye examinations, kidney monitoring, thyroid studies, electrocardiography, neurologic care, or avoidance of specific medications. “Nonsyndromic so far” should be used cautiously when extra-auditory features can develop later.

Carrier result

One pathogenic variant in a recessive gene usually indicates carrier status. Carriers generally do not have hearing loss from that gene, although exceptions and dominant alleles exist. The result matters for reproductive partner testing and relatives but may not explain the tested person’s hearing.

Negative result

A negative result may be:

  • a true negative for a known family variant;
  • a negative limited GJB2/GJB6 test with many genes unexamined;
  • a negative panel with residual technical and biological limitations;
  • an uninformative result in a family without a known cause.

Clinical care should continue based on hearing status. A child does not need a molecular diagnosis before receiving hearing aids, cochlear implant evaluation, language access, educational services, or communication support.

VUS

A VUS should not be used alone to diagnose a syndrome, predict a child’s hearing, or guide embryo selection. It can become more or less suspicious when it fits the inheritance, is in trans with a known variant, segregates with hearing loss, or has strong functional evidence. Formal reclassification belongs to the laboratory or expert panel.

Unexpected result

Testing can reveal nonpaternity, consanguinity, a condition unrelated to the original concern, or an adult-onset risk. Consent should address these possibilities. Families may also experience a genetic diagnosis differently depending on cultural identity and Deaf community affiliation. Counseling should use neutral language and respect hearing, Deaf, and hard-of-hearing perspectives.

Family risk, treatment, and reproduction

Recurrence risk depends on the inheritance pattern.

For autosomal recessive GJB2-related hearing loss, parents of an affected child are usually carriers. Each future pregnancy has a 25% chance of an affected child, 50% chance of a carrier, and 25% chance of inheriting neither familial variant. An affected person will pass one pathogenic variant to every child; whether a child is affected depends on the reproductive partner.

For autosomal dominant hearing loss, an affected person with one pathogenic variant often has a 50% chance of transmission in each pregnancy, though penetrance and severity can vary.

For mitochondrial hearing loss, the transmission path follows the mitochondrial parent. All children may inherit the variant, but heteroplasmy and penetrance can make outcomes difficult to predict. A person who does not transmit mitochondrial DNA generally does not pass the variant to children.

Targeted testing is appropriate for relatives once the family’s exact variant is known. Testing a newborn or child is justified when the result could guide hearing surveillance, medication avoidance, or evaluation for syndromic complications. Carrier-only testing in children is considered separately because reproductive information may not have immediate benefit.

Genetic diagnosis does not dictate one treatment. Management may include hearing aids, cochlear implants, bone-conduction devices, assistive technology, speech and auditory therapy, sign language, educational accommodations, or a combination chosen by the individual or family. Outcomes depend on age, hearing pattern, auditory nerve integrity, access, goals, and many non-genetic factors.

Some gene findings can inform expectations. Auditory-neuropathy genes may affect device planning; cochlear disorders may respond differently from auditory-nerve disorders. Evidence is evolving, and treatment should not be withheld because a genotype has limited outcome data.

Reproductive options include natural conception, prenatal diagnosis, IVF with PGT-M, donor gametes, adoption, or conception without genetic testing. These choices are personal. Hearing loss has diverse lived experiences, and counseling should not assume that preventing transmission is every family’s goal.

Questions after the report

Use the report to build a concrete checklist:

  1. Does the detected variant pattern match the stated inheritance?
  2. If only one recessive variant was found, were copy-number and regulatory deletions assessed?
  3. Did the assay evaluate GJB6-region deletions and technically difficult genes such as STRC?
  4. Was mitochondrial DNA included, and what tissue and heteroplasmy threshold were used?
  5. Does the gene have syndromic features requiring surveillance?
  6. Is the hearing pattern consistent with the gene and variant?
  7. Which relatives should have targeted testing or audiology?
  8. Does the result create a medication precaution, especially for aminoglycosides?
  9. Would a broader panel, exome/genome analysis, or future reanalysis be useful?
  10. How will VUS reclassification be communicated?

Keep the original laboratory report rather than relying on a portal summary. The exact variant, zygosity, phase, method, and classification are essential for family testing. Ask whether both parents were tested when phase affects the diagnosis.

A negative genetic result should not delay hearing support. Audiologic monitoring may be needed because thresholds can change even when the gene is unknown. Sudden hearing loss, new one-sided loss, severe vertigo, neurologic symptoms, or signs of meningitis require urgent medical evaluation rather than routine genetics follow-up.

Common mistakes include treating one GJB2 variant as a diagnosis, assuming every “GJB6 deletion” directly disrupts GJB6, overlooking maternal inheritance for mtDNA, and using a normal newborn screen to exclude later-onset genetic hearing loss. Another error is equating a molecular diagnosis with a fixed communication or developmental outcome. Early access to language and individualized support remains central regardless of genotype. Reassessment is also reasonable when a child’s audiogram changes, new syndromic features appear, or a previously negative panel becomes outdated as gene evidence and laboratory methods improve.

References

Disclaimer

This article is educational and does not replace audiology, otolaryngology, genetics care, medication advice, or emergency evaluation. Hearing-loss interpretation depends on the exact variant, inheritance pattern, phase, assay coverage, audiogram, medical findings, and family history. Do not change an antibiotic or hearing treatment without discussing the result with the treating clinician.

RELATED ARTICLESMORE FROM AUTHOR